U.S., June 23 -- ClinicalTrials.gov registry received information related to the study (NCT07660341) titled 'SAD Study of CGB3002 in Healthy Participants' on June 16.
Brief Summary: This is a randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of single ascending IV doses of CGB3002 in healthy participants. CGB3002 is being developed to treat Alzheimer's Disease.
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
Alzheimer s Disease
Intervention:
DRUG: CGB3002 0.08 mg/kg
Cohorts 1: healthy participants will be administered a single intravenous dose of CGB3002 at dose level of 0.08 mg/kg.
DRUG: CGB3002 0.4 mg/kg
Cohorts 2: healthy...